Viridian Therapeutics, Inc.

Hybrid

Some members of the team work remotely, while others are co-located in one or more offices.

💼Healthcare, Healthcare

👥11-50

📍Waltham

Viridian Therapeutics, Inc.

About Viridian Therapeutics, Inc.

Viridian Therapeutics, is a biotechnology firm focused on developing optimized antibody-based treatments for rare autoimmune diseases, particularly targeting conditions that are currently underserved by existing therapies.

Viridian Therapeutics, Inc. news and updates

Viridian Therapeutics Inc. partners with Hercules Technology Growth Capital, Inc.

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC ) for up to $75 million.

Jan 1, 2022 | globenewswire.com

Viridian Therapeutics Inc. hires Carrie Melvin as COO

Viridian Therapeutics – Viridian Therapeutics appointed Carrie Melvin as COO, a new position at the company.

Jan 1, 2022 | biospace.com

Viridian Therapeutics Inc. went public on Aug 22nd 22'.

Viridian intends to use the proceeds from the underwritten public offering to further its clinical development programs, as well as for working capital and general corporate purposes.

Aug 14, 2022 | viridiantherapeutics.com

miRagen Therapeutics, Inc. acquired Viridian Therapeutics Inc. on Jan 1st 20'.

miRagen Therapeutics, Inc. (“miRagen”) (NASDAQ: MGEN) today announced it has completed the acquisition of Viridian Therapeutics, Inc. (“Viridian”), a privately held biotechnology company focused on advancing new treatments for patients with diseases that are underserved by today’s therapies.

Oct 28, 2020 | biospace.com